Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer

Publisher： Karger

E-ISSN： 1662-6575|10|2|433-437

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.10, Iss.2, 2017-05, pp. : 433-437

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Study of Pegylated Liposomal Doxorubicin in Platinum-Refractory Epithelial Ovarian Cancer

By  

Oncology, Vol. 67, Iss. 3-4, 2004-11 ,pp. : 183-186

Karger

Access to resources Recommend Favorite

Evidence-based chemotherapeutic management of potentially platinum-sensitive recurrent ovarian cancer

By Markman Maurie  

Therapy, Vol. 7, Iss. 3, 2010-05 ,pp. : 269-275

Future Medicine

Access to resources Recommend Favorite

Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

By  

Oncology, Vol. 71, Iss. 5-6, 2007-09 ,pp. : 320-326

Karger

Access to resources Recommend Favorite

Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial

By  

Oncology, Vol. 76, Iss. 1, 2008-11 ,pp. : 49-54

Karger

Access to resources Recommend Favorite

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

By  

Oncology, Vol. 67, Iss. 3-4, 2004-11 ,pp. : 243-249

Karger

Access to resources Recommend Favorite